Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review.

Front Oncol · 2022 · PMC9730822 · PMID 36505771

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In subsequent 2-year follow-up data published, pembrolizumab showed a trend of OS improvement compared with paclitaxel in patients with PD-L1 CPS ≥1, with a 2-year OS rate of 19.9% vs. 8.5% ( 15 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.